Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brii Biosciences Limited (DE:7SS)
FRANKFURT:7SS
RESEARCH TOOLSreports
Holding DE:7SS?
Track your performance easily
7SS Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.10 - €0.39
Previous Close€0.12
Volume0.00
Average Volume (3M)743.00
Market Cap
€90.17M
Enterprise Value-€333.49M
Total Cash (Recent Filing)¥3.22B
Total Debt (Recent Filing)¥17.47M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 21, 2025EPS Estimate
-€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares OutstandingN/A
10 Day Avg. Volume100
30 Day Avg. Volume743
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.12Price Target Upside2.56% Upside
Rating ConsensusHold
Number of Analyst Covering1
Brii Biosciences Limited News
PremiumCompany Announcements
Brii Biosciences Reports Promising Phase 2 Results
PremiumCompany Announcements
Brii Biosciences Adjusts Share Options to Align Interests
PremiumCompany Announcements
Brii Biosciences Reports Mixed Mid-Year Financials
PremiumCompany Announcements
Brii Biosciences Schedules Key Financial Review Meeting
PremiumCompany Announcements
Brii Biosciences Confirms Stability Amid Partner’s InsolvencyPremiumCompany Announcements
Brii Biosciences Announces Board Composition
PremiumCompany Announcements
Brii Biosciences Shareholders Approve Key Resolutions
PremiumCompany Announcements
Brii Biosciences’ Promising HBV Treatment AdvancesBulls Say, Bears Say
Bulls Say
Clinical Results'179 combined with elebsiran induced significant HBV-specific B and T cell responses, which may be important for immune reactivation.
Immune ResponseParticipants in the combo group who maintained HBsAg loss while off NUC treatment also had higher anti-HBs, suggesting the combo regimen could improve immune reactivation.
Treatment EfficacyNo participant who discontinued NUC treatment required re-treatment, and no HBsAg rebound was observed in those with anti-HBs ≥ 100 IU/L at EOT.
Bears Say
EarningsHBV peak sales estimates reduced from ~$1.2B to ~$600M due to potentially slower uptake in China and possible pricing pressure from competition and national reimbursement trends.
Financial PerformanceFactoring in multiple raises due to potential prolonged HBV trial costs and unclear regulatory timelines, which would be dilutive.
Regulatory TimelineThe commercial launch of Brii's HBV combo regimen has been delayed by 2 years due to potentially slower drug development and regulatory timelines in China.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.10 and its highest was €0.39 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Currently, no data Available
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 21, 2025 which is in 118 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 19, 2024. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of -€0.045 by -€0.005.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Undervalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate is -€0.03.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 731,194,030 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.05 in its last earnings report, missing expectations of -€0.045. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
---
Brii Biosciences Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.43%
12-Months-Change
Fundamentals
Return on Equity
-8.93%
Trailing 12-Months
Asset Growth
-7.83%
Trailing 12-Months
Company Description
Brii Biosciences Limited
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for significant infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have significant public health burdens in China and worldwide.
---
7SS Stock 12 Month Forecast
Average Price Target
€0.12
▲(2.56% Upside)
Technical Analysis
---